ALK and non-small cell lung carcinoma: <i>ALK</i>-positive tumors are sensitive to ALK tyrosine kinase inhibitors (TKIs), thus <i>ALK</i>-positive non-small-cell lung cancer (NSCLC) is currently spearheading precision medicine in thoracic oncology, with three generations of approved ALK inhibitors in clinical practice.